Investigating the effect of SGLT2 inhibitors in preventing the reduction of ejection fraction in patients with myocardial infraction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250701066325N1

Enrollment

Registered

2025-07-21

Start date

2025-07-06

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: From the first day of Myocardial infarction to the 30th day, one empagliflozin 10 tablet from Abidi Pharmacy Company will be taken daily. Intervention 2: Control gr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with myocardial infraction Consent to participate in the study

Exclusion criteria

Exclusion criteria: Dissatisfaction

Design outcomes

Primary

Measure	Time frame
Ejection Fraction. Timepoint: Investigation of Ejection fraction on the 1st and 30th day after Myocardial infarction. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlemeh Nourji

Islamic Azad University

Alemehnourji@gmail.com+98 11 3325 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026